PitchSend

Investor Presentaiton

NZ$ Million Hospital/Rx channel underpins Asian result Asia total revenue $6.0 $5.0 $4.0 $3.0 $2.1 $2.0 $1.3 $1.0 $0.0 $4.9 $4.4 Asia channel 1H 9% 10% 22% 28% 1H 2021 1H 2022 62% 32% 70% $2.9 $2.2 FY2018 FY 2019 FY2020 FY2021 1H FY22 - OTC ■Prescription ■ Hospital • Hospital/Rx sales rise 32% due to strong anti-bacterial sales • TMall store, aimed at reaching into China and building brand recognition, making a growing contribution to OTC sales. To be extended • Growth diluted by weaker sales to Singapore of Maxigesic, which stockpiled the medicine in the prior year. • ASX-listed McPherson's to pick up OTC distribution in Singapore AFTpharmaceuticals Page 8

View entire presentation